Point72 Asset Management L.P. bought a new stake in Acceleron Pharma Inc (NASDAQ:XLRN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 72,900 shares of the biopharmaceutical company’s stock, valued at approximately $2,721,000. Point72 Asset Management L.P. owned about 0.16% of Acceleron Pharma at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. Quantbot Technologies LP grew its holdings in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 2,352 shares during the period. BNP Paribas Arbitrage SA lifted its position in Acceleron Pharma by 969.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 3,288 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Acceleron Pharma during the 3rd quarter worth approximately $225,000. PNC Financial Services Group Inc. lifted its position in Acceleron Pharma by 57.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Acceleron Pharma during the 3rd quarter worth approximately $266,000. 85.70% of the stock is owned by hedge funds and other institutional investors.
Shares of Acceleron Pharma Inc (NASDAQ:XLRN) traded up $1.21 during mid-day trading on Friday, reaching $45.12. The company’s stock had a trading volume of 666,831 shares, compared to its average volume of 359,233. Acceleron Pharma Inc has a 12 month low of $23.07 and a 12 month high of $45.52. The firm has a market cap of $1,930.00, a price-to-earnings ratio of -17.49 and a beta of 1.59.
Acceleron Pharma (NASDAQ:XLRN) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.02. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business’s revenue was up .0% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.55) EPS. sell-side analysts forecast that Acceleron Pharma Inc will post -2.65 earnings per share for the current year.
Several equities analysts recently commented on the company. Cann reissued a “hold” rating on shares of Acceleron Pharma in a research report on Monday. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research report on Monday. BidaskClub raised Acceleron Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. HC Wainwright reissued a “buy” rating and set a $62.00 price target on shares of Acceleron Pharma in a research report on Monday, December 11th. Finally, Credit Suisse Group set a $51.00 price target on Acceleron Pharma and gave the company a “buy” rating in a research report on Tuesday, November 14th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $44.56.
In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 4,000 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $42.42, for a total value of $169,680.00. Following the completion of the sale, the chief financial officer now owns 45,300 shares in the company, valued at approximately $1,921,626. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kevin F. Mclaughlin sold 19,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $42.89, for a total value of $814,910.00. Following the completion of the sale, the chief financial officer now owns 45,300 shares of the company’s stock, valued at approximately $1,942,917. The disclosure for this sale can be found here. Insiders sold a total of 135,021 shares of company stock worth $5,034,598 in the last ninety days. Insiders own 3.90% of the company’s stock.
Acceleron Pharma Profile
Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.